Related Experiment Video
Updated: Mar 21, 2026
10:04
Enhancing Tumor Content through Tumor Macrodissection
Published on: February 12, 2022
12.7K
[Primary Breast Diffuse Large B Cell Lymphoma: Summarization of 12 Cases]
Ying Huang1, Li Wang1, Lei Fan1
1Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Provincial People's Hospital, Nanjing 210029, Jiangsu Province, China.
Zhongguo Shi Yan Xue Ye Xue Za Zhi
|May 7, 2016
Summary
Primary breast diffuse large B-cell lymphoma (DLBCL) is rare, often presenting as a painless breast mass. Patients respond well to chemotherapy, indicating a favorable prognosis for this uncommon lymphoma subtype.
Area of Science:
- Hematology
- Oncology
- Pathology
Background:
- Primary breast diffuse large B-cell lymphoma (PB-DLBCL) is an exceptionally rare non-Hodgkin lymphoma.
- Understanding its clinicopathological and immunophenotypic characteristics is crucial for diagnosis and treatment.
Purpose of the Study:
- To investigate the clinicopathological manifestations of PB-DLBCL.
- To analyze the immunophenotypic features and identify prognostic factors in PB-DLBCL patients.
Main Methods:
- Retrospective study of 12 PB-DLBCL cases.
- Diagnosis based on the 2008 World Health Organization classification.
- Analysis of clinical presentation, Ann Arbor staging, and molecular subtypes (GCB vs. non-GCB).
Main Results:
- Most patients presented with a painless unilateral breast mass.
- Cases were predominantly in Ann Arbor stage I (41.7%) and II (58.3%).
- The majority (89.9%) were non-germinal center B-cell (non-GCB) subtypes, with 11.1% being GCB subtype.
Conclusions:
- PB-DLBCL is a rare entity lacking specific clinical features.
- Patients with PB-DLBCL demonstrate sensitivity to chemotherapy.
- The study indicates a good prognosis for patients treated for PB-DLBCL.
